NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Forecast, Price & News

$0.36

-0.01 (-2.73%)

(As of 09/28/2023 ET)

Compare

Today's Range: $0.35
▼
$0.37
50-Day Range: $0.36
▼
$0.64
52-Week Range: $0.35
▼
$1.70

Volume: 354,584 shs
Average Volume: 750,001 shs
Market Capitalization: $40.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Precision BioSciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 742.5% Upside
$3.00 Price Target
Short Interest: Healthy
1.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.99
Upright™ Environmental Score
News Sentiment: 0.54
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.77) to ($0.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

269th out of 969 stocks

Biological Products, Except Diagnostic Industry

43rd out of 161 stocks

3.3

Analyst's Opinion

Consensus Rating
Precision BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Precision BioSciences has a forecasted upside of 742.5% from its current price of $0.36.
Amount of Analyst Coverage
Precision BioSciences has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.75% of the float of Precision BioSciences has been sold short.
Short Interest Ratio / Days to Cover
Precision BioSciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Precision BioSciences has recently decreased by 3.66%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Precision BioSciences does not currently pay a dividend.
Dividend Growth
Precision BioSciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Precision BioSciences has received a 72.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Precision BioSciences is -0.99.

2.5

News and Social Media Coverage

News Sentiment
Precision BioSciences has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Precision BioSciences this week, compared to 6 articles on an average week.
Search Interest
10 people have searched for DTIL on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.
MarketBeat Follows
7 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Precision BioSciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.50% of the stock of Precision BioSciences is held by insiders.
Percentage Held by Institutions
Only 37.99% of the stock of Precision BioSciences is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.77) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Precision BioSciences is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Precision BioSciences is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Precision BioSciences has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL Price History

30 days | 90 days | 365 days | Advanced Chart

DTIL Stock News Headlines

September 24, 2023 | tmcnet.com

Vial to Sponsor the 21st Precision in Clinical Trials Summit 2023 in San Diego, CA

September 20, 2023 | americanbankingnews.com

Precision BioSciences' (DTIL) Buy Rating Reaffirmed at HC Wainwright

September 29, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 19, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Precision BioSciences

September 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Precision BioSciences (DTIL)

September 16, 2023 | finance.yahoo.com

This Precision BioSciences Insider Increased Their Holding By 38% Last Year

September 15, 2023 | tmcnet.com

Precision Dropper - The Next Revolution in Eye Health

September 15, 2023 | businesswire.com

Global Precision Fermentation Ingredients Market: Explosive Growth with 44.0% CAGR, Reaching $36.3 Billion by 2030 - ResearchAndMarkets.com

September 29, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 13, 2023 | markets.businessinsider.com

BTIG Sticks to Their Buy Rating for Precision BioSciences (DTIL)

September 12, 2023 | finance.yahoo.com

Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

September 8, 2023 | msn.com

Ratnaveer Precision Engineering shares to list on September 11, marking the first T+3 debut

September 8, 2023 | msn.com

Ratnaveer Precision IPO allotment – how to check allotment, GMP, listing date and more

September 7, 2023 | marketwatch.com

Precision Drilling to Acquire CWC Energy Services in C$141M Deal

September 6, 2023 | bizjournals.com

Abrasive Technologies acquires Cincinnati machining, mining company Swiss Precision

September 6, 2023 | finance.yahoo.com

Precision BioSciences to Attend and Present at Upcoming September Investor Conferences

September 6, 2023 | msn.com

Ratnaveer Precision Engineering IPO subscribed 42 times on Day 3 so far

September 5, 2023 | msn.com

Ratnaveer Precision Engineering IPO subscribed nearly 16x so far on Day 2. Check GMP and other details

September 4, 2023 | msn.com

Ratnaveer Precision Engineering IPO subscribed 5.7x on day 1

September 4, 2023 | msn.com

Ratnaveer Precision Engineering Limited IPO Subscribed Fully On First Day; Check GMP, Price, Allotment Date, More

August 31, 2023 | finance.yahoo.com

Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

August 30, 2023 | msn.com

Ratnaveer Precision Engineering IPO to open on September 4: Check price band & other details

August 23, 2023 | technews.tmcnet.com

Precision Farming Market worth $21.9 billion by 2031 - Exclusive Report by MarketsandMarkets™

August 22, 2023 | finance.yahoo.com

Why Durham biotech's pivot means smaller, leaner company

August 18, 2023 | msn.com

Dynalife ownership to transfer all staff, operations, physical labs to Alberta Precision Labs

August 18, 2023 | finance.yahoo.com

After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)

August 17, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Precision BioSciences

See More Headlines

Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

DTIL Company Calendar

Last Earnings: 8/04/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DTIL
CUSIP: N/A
CIK: 1357874
Web: www.precisionbiosciences.com
Phone: (919) 314-5512
Fax: N/A
Employees: 192
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +742.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-111,640,000.00
Net Margins: -192.10%
Pretax Margin: -192.10%
Return on Equity: -163.24%
Return on Assets: -39.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.62
Quick Ratio: 2.62

Sales & Book Value

Annual Sales: $25.10 million
Price / Sales: 1.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 115,070,000
Free Float: 105,290,000
Market Cap: $40.98 million
Optionable: Not Optionable
Beta: 1.31

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Michael Amoroso (Age 45)
Pres, CEO & Director
Comp: $979.04k

Mr. John Alexander Kelly R.Ph. (Age 56)
Chief Financial Officer
Comp: $623.58k

Mr. Dario Scimeca (Age 47)
Gen. Counsel & Sec.
Comp: $576.43k

Dr. Derek Jantz Ph.D. (Age 47)
Co-Founder & Chief Science Advisor

Dr. Jefferson J. Smith Ph.D. (Age 50)
Co-Founder & Chief Research Officer

Mr. Shane Barton (Age 52)
VP, Corp. Controller & Principal Accounting Officer

Mei Burris
Director of Investor Relations & Fin.

Mr. Bruce Stevens
VP of Quality & Compliance

Maurissa Messier
Sr. Director of Corp. Communications

Ms. Juli Blanche
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DTIL Stock - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DTIL shares.
View DTIL analyst ratings or view top-rated stocks.
What is Precision BioSciences' stock price forecast for 2023?: 3 brokerages have issued twelve-month target prices for Precision BioSciences' shares. Their DTIL share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 742.5% from the stock's current price.
View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts.
How have DTIL shares performed in 2023?: Precision BioSciences' stock was trading at $1.19 at the beginning of 2023. Since then, DTIL stock has decreased by 70.1% and is now trading at $0.3561.
View the best growth stocks for 2023 here.
When is Precision BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our DTIL earnings forecast.
How were Precision BioSciences' earnings last quarter?: Precision BioSciences, Inc. (NASDAQ:DTIL) released its quarterly earnings results on Friday, August, 4th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.13. The firm had revenue of $19.79 million for the quarter, compared to analyst estimates of $6.58 million. Precision BioSciences had a negative trailing twelve-month return on equity of 163.24% and a negative net margin of 192.10%.
What ETF holds Precision BioSciences' stock ?: Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.
What is Matt Kane's approval rating as Precision BioSciences' CEO?: 12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).
When did Precision BioSciences IPO?: (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.
What is Precision BioSciences' stock symbol?: Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."
How do I buy shares of Precision BioSciences?: Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Precision BioSciences' stock price today?: One share of DTIL stock can currently be purchased for approximately $0.36.
How much money does Precision BioSciences make?: Precision BioSciences (NASDAQ:DTIL) has a market capitalization of $40.98 million and generates $25.10 million in revenue each year. The company earns $-111,640,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.
How many employees does Precision BioSciences have?: The company employs 192 workers across the globe.
How can I contact Precision BioSciences?: Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The official website for the company is www.precisionbiosciences.com. The company can be reached via phone at (919) 314-5512 or via email at jwong@bplifescience.com.

This page (NASDAQ:DTIL) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial